Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.37 | -5.92% | 37.65 | 37.65 | 37.89 | 39.663444 | 37.44 | 38.7899 | 3,904,307 | 21:05:18 |
From Apr 2023 to Apr 2025
By Adria Calatayud
Roche Holding's Alecensa drug reduced the risk of disease recurrence or death in a phase 3 trial for a type of non-small cell lung cancer at an early stage, the company said Wednesday.
The Swiss pharmaceutical giant said a primary analysis of the study results showed Alecensa reduced the risk of disease recurrence or death by 76% compared with platinum-based chemotherapy, demonstrating a statistically significant and clinically meaningful improvement in disease-free survival.
The safety and tolerability of the drug in the trial were consistent with previous studies and no unexpected safety findings were observed, Roche said.
The company said it is conducting further analysis of overall survival estimates given that data were immature at this stage.
Roche will submit data from the trial to global health authorities, including the U.S. Food and Drug Administration and the European Medicines Agency, it said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 18, 2023 01:59 ET (05:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
